CELGENE CORPORATION

πŸ‡ΊπŸ‡ΈUnited States
Ownership
-
Employees
-
Market Cap
-
Website

Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment

Phase 1
Completed
Conditions
Interventions
First Posted Date
2020-10-05
Last Posted Date
2024-07-15
Lead Sponsor
Celgene
Target Recruit Count
40
Registration Number
NCT04573582
Locations
πŸ‡ΊπŸ‡Έ

Local Institution - 002, Miami, Florida, United States

πŸ‡ΊπŸ‡Έ

Volunteer Research Group and New Orleans Center for Clinical Research - Knoxville, Knoxville, Tennessee, United States

πŸ‡ΊπŸ‡Έ

Local Institution - 003, Orlando, Florida, United States

A Study to Evaluate the Metabolism and Excretion of [14C]-CC-92480 in Healthy Male Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2020-09-23
Last Posted Date
2021-11-29
Lead Sponsor
Celgene
Target Recruit Count
8
Registration Number
NCT04560738
Locations
πŸ‡ΊπŸ‡Έ

Covance Clinical Research Unit Inc, Madison, Wisconsin, United States

A Study to Evaluate the Relative Bioavailability of a Pediatric Granule Formulation of Ozanimod in Healthy Adult Subjects

Phase 1
Completed
Conditions
Interventions
First Posted Date
2020-08-27
Last Posted Date
2021-09-20
Lead Sponsor
Celgene
Target Recruit Count
56
Registration Number
NCT04528290
Locations
πŸ‡ΊπŸ‡Έ

PPD Phase 1 Clinic, Austin, Texas, United States

A Study to Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell Transfusions

Phase 2
Active, not recruiting
Conditions
Interventions
First Posted Date
2020-07-20
Last Posted Date
2023-10-12
Lead Sponsor
Celgene
Target Recruit Count
30
Registration Number
NCT04477850
Locations
πŸ‡―πŸ‡΅

Local Institution - 203, Nagasaki-shi, Nagasaki, Japan

πŸ‡¨πŸ‡³

Local Institution - 105, Guangzhou, China

πŸ‡¨πŸ‡³

Local Institution - 103, Guangzhou, China

and more 21 locations

A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

Phase 1
Active, not recruiting
Conditions
Interventions
First Posted Date
2020-07-09
Last Posted Date
2023-10-04
Lead Sponsor
Celgene
Target Recruit Count
62
Registration Number
NCT04464798
Locations
πŸ‡«πŸ‡·

Local Institution - 205, Pessac, France

πŸ‡°πŸ‡·

Local Institution - 501, Seoul, Korea, Republic of

πŸ‡ΊπŸ‡Έ

Local Institution - 105, Lake Mary, Florida, United States

and more 23 locations

A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

Phase 1
Active, not recruiting
Conditions
Interventions
First Posted Date
2020-06-25
Last Posted Date
2024-09-30
Lead Sponsor
Celgene
Target Recruit Count
31
Registration Number
NCT04446650
Locations
πŸ‡―πŸ‡΅

Local Institution - 016, Osaka, Japan

πŸ‡―πŸ‡΅

Local Institution - 014, Sapporo, Japan

πŸ‡―πŸ‡΅

Local Institution - 021, Suwa, Nagano, Japan

and more 18 locations

A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 1
Completed
Conditions
Interventions
First Posted Date
2020-06-16
Last Posted Date
2024-07-25
Lead Sponsor
Celgene
Target Recruit Count
16
Registration Number
NCT04434196
Locations
πŸ‡ΊπŸ‡Έ

Local Institution - 104, Columbus, Ohio, United States

πŸ‡ΊπŸ‡Έ

Local Institution - 106, Boston, Massachusetts, United States

πŸ‡ΊπŸ‡Έ

Local Institution - 101, Portland, Oregon, United States

and more 12 locations

Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer

Phase 1
Active, not recruiting
Conditions
Interventions
First Posted Date
2020-06-11
Last Posted Date
2024-10-26
Lead Sponsor
Celgene
Target Recruit Count
250
Registration Number
NCT04428788
Locations
πŸ‡ΊπŸ‡Έ

Local Institution - 116, Stanford, California, United States

πŸ‡ΊπŸ‡Έ

Local Institution - 122, Washington, District of Columbia, United States

πŸ‡ΊπŸ‡Έ

Local Institution - 103, Sarasota, Florida, United States

and more 16 locations

Study to Evaluate the Pharmacokinetic Comparability of CC-93538 From Two Different Drug Concentrations in Healthy Adult Subjects

Phase 1
Completed
Conditions
Interventions
First Posted Date
2020-05-04
Last Posted Date
2021-09-28
Lead Sponsor
Celgene
Target Recruit Count
52
Registration Number
NCT04373187
Locations
πŸ‡ΊπŸ‡Έ

PPD Phase 1 Clinic, Austin, Texas, United States

A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers

Phase 2
Completed
Conditions
Interventions
First Posted Date
2020-04-17
Last Posted Date
2024-02-21
Lead Sponsor
Celgene
Target Recruit Count
92
Registration Number
NCT04350463
Locations
πŸ‡ΊπŸ‡Έ

Local Institution - 107, Fort Sam Houston, Texas, United States

πŸ‡ΊπŸ‡Έ

Local Institution - 105, Canton, Ohio, United States

πŸ‡ΊπŸ‡Έ

Local Institution - 110, Houston, Texas, United States

and more 34 locations
Β© Copyright 2024. All Rights Reserved by MedPath